Despite the wide variety of Covid-19 symptoms, pain and the related mechanisms underlying unsettled nociceptive status are still under-prioritized. Understanding the complex network of Covid-19-related pain may result in new lines of study.
Product: Human Substance P (SP) ELISA Kit
Pub Date:2022-01-26 IF: 3.183
Colorectal cancer is a common type of cancer with high incidence and poor prognosis. Increased expression of myosin light chain 9 (MYL9) has been reported in early-stage and recurrent colorectal cancer tissues.
Product: Human Vascular Endothelial cell Growth Factor (VEGF) ELISA Kit
Pub Date:2022-01-03 IF: 3.269
Type 2 diabetes mellitus (T2DM) is a systematic multi-organ metabolic disease, which is characterized by the dynamic interplay among different organs.The increasing incidence of T2DM reflects an urgent need for the development of in vitro human-relevant models for disease study and drug therapy.
Product: Human Albumin (ALB) ELISA Kit Human Insulin (INS) ELISA Kit
Pub Date:2021-12-23 IF: 16.806
Anemarrhenae rhizome and Phellodendri cortex have historically been used for the treatment of precocious puberty (PP) in oriental medicine.Our study aimed to evaluate the effect of APE, a mixture of the extracts from these herbs, against danazol-induced PP in female rats.
Product: Rat Estradiol (E2) ELISA Kit Rat Luteinizing hormone (LH) ELISA Kit Rat Follicle-stimulating hormone (FSH) ELISA Kit Rat Alkaline phosphatase (ALP) ELISA Kit
Pub Date:2021-12-22 IF: 3.935
Central obesity and insulin resistance are associated with metabolic syndrome (MetS) which is aggravated by diet and sedentary lifestyle. Athrixia phylicoides (AP) is reported by rural communities to have medicinal benefits associated with MetS such as obesity and type 2 diabetes.
Product: Rat Free fatty acids (FFA) ELISA Kit
Pub Date:2021-11-29 IF: 3.470
Objective To investigate the effects of sepsis and HIF-1α agonist or inhibitor on intestinal mucosal barrier function.Methods SD rats were randomly divided into sham operation group (sham), Sepsis group treating with cecal ligation and perforation (CLP), Sepsis+HIF-1α agonist group (sepsis + DMOG) receiving intraperitoneal injection of HIF-1α agonist DMOG (40 mg/kg) for 7 consecutive days before CLP, Sepsis+HIF-1α inhibitor group (sepsis+BAY87-2243) orally administered with HIF-1α inhibitor BAY87-2243 (9 mg/kg) for 3 consecutive days before CLP.
Product: Rat D-lactic acid ELISA Kit
Pub Date:2021-10-27 IF: 0.552